Asthma; Eosinophilic
28
3
9
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.7%
3 terminated out of 28 trials
70.0%
-16.5% vs benchmark
36%
10 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (28)
Mepolizumab and Physical Activity in Severe Asthma
SIM0718 Treatment of Asthma Clinical Study
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma
Homeostatic Roles of Eosinophils in Asthma
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Asthma Control in a Dutch Primary Care Population
Predictive Signature of Benralizumab Response
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma